Atos and Huma, the digital health companies, have announced a five-year partnership to improve healthcare and research with remote monitoring technologies.

The partnership will focus on Huma’s modular platform which can power digital ‘hospitals at home’ up to national scale, as well as support pharmaceutical and research industries to run complex global decentralised clinical trials.

The platform is already used in the US and across Europe for illnesses ranging from atrial fibrillation to diabetes and Covid-19.

Atos will use its experience in implementing and scaling complex transformation projects to accelerate adoption of Huma’s technology.

This will include investment by Atos worth up to €20 million split across R&D and go-to-market resources, including dedicated consulting and sales personnel.

The investment in R&D will fast-track the integration of the Huma platform with other leading clinical platforms, as well as develop a dedicated video module.

“We have great excitement about this partnership, as we are convinced that Atos and Huma can drive a systemic shift from reactive to proactive models of care,” said Robert Vassoyan, head of health and life sciences business, Atos. “Huma is the company we’ve been looking for in this important mission that resonates with each of us personally as we seek to improve the lives of our family, friends, neighbors and society. This is a partnership worthy of the mission.”

Dan Vahdat, chief executive and founder of Huma, said: “This partnership takes us to a new league - we have already shown that we can create a service for a new disease area in a matter of weeks, as we did during the pandemic, and that we can go live with over 100 clinics in a day. Atos will supercharge our work so we can offer services at scale, anywhere in the world across delivery of care and pharma collaborations leading to more people living longer, fuller lives.”

Share Story: